XBRU:UCB (Belgium)  
UCB SA logo

UCB SA

€ 73.14 (-0.68%) Aug 12
P/E:
16.04
P/B:
1.55
Market Cap:
€ 13.84B ($ 14.06B)
Enterprise V:
€ 15.86B ($ 16.11B)
Volume:
273.68K
Avg Vol (2M):
313.08K
Also Trade In:
Volume:
273.68K
Market Cap €:
13.84B
Market Cap $:
14.06B
PE Ratio:
16.04
Avg Vol (2-Month):
313.08K
Enterprise Value €:
15.86B
Enterprise Value $:
16.11B
PB Ratio:
1.55
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download Tutorials

Business Description

Description
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

Financials (Next Earnings Date:2023-02-24 Est.)

XBRU:UCB's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 5,924
EPS (TTM) (€) 4.56
Beta 0.43
Volatility % 35.42
14-Day RSI 30.85
14-Day ATR (€) 1.887516
20-Day SMA (€) 77.336
12-1 Month Momentum % -13.31
52-Week Range (€) 72.34 - 116.05
Shares Outstanding (Mil) 189.17

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 8
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

UCB SA Filings

Document Form Filing Date
No Filing Data